Synergistic effect and its possible mechanisms of lidamycin in combination with TRAIL in NSCLC

Yaoxue Xuebao

Volumn 45, Issue 10, 2010, Pages 1247-1253

  Yang, Jie ^a   Chen, Shu Zhen ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Apoptosis; Death receptor 5; Lidamycin; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; DEATH RECEPTOR 5; HOE 33342; LIDAMYCIN; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION; STAINING; WESTERN BLOTTING;

AMINOGLYCOSIDES; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CASPASE 8; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENEDIYNES; HUMANS; LUNG NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 78650186409     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Kotteas EA, Charpidou AG, Syrigos KN. Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors [J]. Anticancer Drugs, 2010, 21: 151-168.
2. Shao RG, Zhen YS. Enediyne anticancer antibiotic lidamycin: chemistry, biology and pharmacology [J]. Anticancer Agents Med Chem, 2008, 8: 123-131.
3. Otani T, Yasuhara T. Purification and primary structure of C1027 AG, a selective antagonist of antitumor antibiotic C1027 from Streptomyces globisporus [J]. Agric Biol Chem, 1991, 55: 407-417.
4. Zhang SH, Chen J, Jiang M, et al. Lidamycin induces apoptosis of human gastric carcinoma BGC823 cells and inhibits xenograft growth in nude mice [J]. Acta Pharm Sin, 2008, 43: 601-604.
5. Liu YP, Li QS, Huang YR, et al. Tissue distribution and excretion of 125I-lidamycin in mice and rats [J]. World J Gastroenterol, 2005, 11: 3281-3284. (Pubitemid 40973901)
6. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of new member of the TNF family that induces apoptosis [J]. Immunity, 1995, 3: 673-682.
7. Wajant H, Pfizenmaier K, Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy [J]. Apoptosis, 2002, 7: 449-459.
8. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors [J]. Cell Death Differ, 2003, 10: 66-75.
9. Spierings DC, de Vries EG, Timens W, et al. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors [J]. Clin Cancer Res, 2003, 9: 3397-3405. (Pubitemid 37082735)
10. Holoch PA, Griffith TS. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies [J]. Eur J Pharmacol, 2009, 625: 63-72.
11. Chen SZ. Progress on targeting TRAIL'S receptor as antitumor strategy [J]. Acta Pharm Sin, 2009, 44: 1336-1342.
12. Seitz SJ, Schleithoff ES, Koch A, et al. Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway [J]. Int J Cancer, 2010, 126: 2049-2066.
13. Gressner O, Schilling T, Lorenz K, et al. TAp63a induces apoptosis by activating signaling via death receptors and mitochondria [J]. EMBO J, 2005, 24: 2458-2471.
14. Han J, Hou W, Goldstein LA, et al. Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells [J]. J Biol Chem, 2008, 283: 19665-19677.
15. Drosopoulos KG, Roberts ML, Cermak L, et al. Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway [J]. J Biol Chem, 2005, 280: 22856-22867. (Pubitemid 40853193)
16. Shao RG Small interfering RNA mediated multi-target therapy of cancer [J]. Acta Pharm Sin, 2009, 44: 219-225.